<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82938">
  <stage>Registered</stage>
  <submitdate>23/07/2008</submitdate>
  <approvaldate>15/09/2008</approvaldate>
  <actrnumber>ACTRN12608000458336</actrnumber>
  <trial_identification>
    <studytitle>A phase 1 clinical trial of peptide-pulsed monocyte-derived dendritic cell vaccination to expand adoptively transferred cytomegalovirus -specific cytotoxic T lymphocytes after allogeneic stem cell transplantation</studytitle>
    <scientifictitle>A phase 1 clinical trial of peptide-pulsed monocyte-derived dendritic cell vaccination to expand adoptively transferred CMV-specific cytotoxic T lymphocytes after allogeneic stem cell transplantation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cytomegalovirus (CMV) reactivation and disease</healthcondition>
    <conditioncode>
      <conditioncode1>Blood</conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Donor derived dendritic cells (DC) pulsed with cytomegalovirus (CMV) antigen and/or CMV antigen specific T cells will be injected into patients following haemopoietic stem cell transplantation. There will be 3 arms: Arm 1 - CMV cytotoxic T lymphocyte (CTL) infusion only; Arm 2 - DC vaccine with CMV cytotoxic T lymohocyte infusion; Arm 3 - DC vaccination only.
Doses are:
CMV cytotoxic T lymphocytes - 2x10^7 per square metre of body surface area once post transplant
DC vaccine - 2x10^6 per sqaure metre of body surface area twice at 7 day interval</interventions>
    <comparator>The DC+CMV CTL arm will be compared with DC alone and CMV CTL alone. These will all be compared with historical controls.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety - acute toxicity. Measured by clinical history, physical examination and observation of vital signs before, during and for 4 hours after the infusion of lymphocytes or injection of dendritic cells.</outcome>
      <timepoint>4 hours post infusion/injection.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety - graft vs host disease. Measured by a standard clinical grading system as grade I-IV.</outcome>
      <timepoint>12 months post infusion/injection</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety - progressive disease. Measured by the detection of recurrent malignancy on full blood examination or bone marrow biopsy.</outcome>
      <timepoint>12 months post infusion/injection</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Use of antiviral therapy</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CMV specific immunological response. This is measured by in vitro assay of T cell response to CMV antigen (flow cytometry using tetramer/pentamer, ELISPOT and Cytokine Flow Cytometry).</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CMV reactivation as measured by whole blood PCR or CMV disease diagnosed on standard clinical criteria.</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Recipient and donor pairs with haemopoietic stem cell transplant
Human Leukocyte Antigen (HLA)-A2 positive
CMV seropositive donor
Fully HLA-matched or one antigen mismatched allogeneic transplant</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>HLA-A2 negative or CMV seronegative donor</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>Allocation of treatment is based on the time of recruitment-
Patients 1 to 6 - Arm 1
Patients 7-12 - Arm 2
Patients 13-18 - Arm 3</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Allocation of treatment is based on the time of recruitment-
Patients 1 to 6 - Arm 1
Patients 7-12 - Arm 2
Patients 13-18 - Arm 3</designfeatures>
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/08/2008</anticipatedstartdate>
    <actualstartdate>7/08/2012</actualstartdate>
    <anticipatedenddate>31/03/2014</anticipatedenddate>
    <actualenddate />
    <samplesize>18</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Westmead Hospital - Westmead</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Western Sydney Local Health District</primarysponsorname>
    <primarysponsoraddress>Westmead Hospital
Hawkesbury Rd
Westmead
NSW 2145</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Westmead Hospital</fundingname>
      <fundingaddress>Hawkesbury Rd
Westmead
NSW 2145</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>The Cancer Council NSW</fundingname>
      <fundingaddress>153 Dowling Street
Woolloomooloo
NSW 2011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A preliminary study of the use of immune cells from transplant donors to prevent cytomegalovirus infection in recipients of blood stem cell transplants. The study hypothesis is that stimulation of infused CMV specific lymphocytes by CMV peptide pulsed DC given as a vaccine will enhance immune reconstitution. The study will use two different sorts of immune cells (called T lymphocytes and dendritic cells). These cells will be prepared in the laboratory and given back to patients after transplant to try to prevent diseases caused by the CMV virus.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sydney West Area Health Service HREC</ethicname>
      <ethicaddress>Westmead Hospital
Hawkesbury Rd
Westmead
NSW 2145</ethicaddress>
      <ethicapprovaldate>10/10/2005</ethicapprovaldate>
      <hrec>HREC2005/8/4.22(2170)</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>David Gottlieb</name>
      <address>University of Sydney, Western Clinical School
Westmead Hospital
Westmead
NSW 2145</address>
      <phone>+61298456033</phone>
      <fax />
      <email>david.gottlieb@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>David Gottlieb</name>
      <address>University of Sydney, Western Clinical School
Westmead Hospital
Westmead
NSW 2145</address>
      <phone>+61298456033</phone>
      <fax />
      <email>david.gottlieb@sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Professor David Gottlieb</name>
      <address>University of Sydney, Western Clinical School
Westmead Hospital
Westmead
NSW 2145</address>
      <phone>+61298456033</phone>
      <fax />
      <email>david.gottlieb@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>David Gottlieb</name>
      <address>University of Sydney, Western Clinical School Westmead Hospital Westmead NSW 2145</address>
      <phone>+61298456033</phone>
      <fax />
      <email>david.gottlieb@sydney.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>